Recombinant Apium graveolens Allergen Api g 5

What is Api g 5 and what protein family does it belong to?

Api g 5 is a major allergen isolated from celery (Apium graveolens) that belongs to the flavoprotein family. It has been characterized at the molecular level alongside other celery allergens including Api g 1 (PR-10 protein), Api g 2 (LTP1), Api g 4 (profilin), and Api g 6 (LTP2) . As a flavoprotein, Api g 5 likely contains a flavin cofactor (FAD or FMN) that contributes to its structural and functional properties. The protein's molecular characterization reveals specific features that contribute to its allergenicity and potential cross-reactivity patterns with homologous proteins from other plant sources.

Methodologically, protein family classification requires sequence alignment algorithms, phylogenetic analysis, and structural comparisons with known flavoproteins. Experimental confirmation typically involves spectroscopic analysis to detect the characteristic flavin absorption spectrum (350-450 nm) and biochemical assays to verify enzymatic activity typical of flavoproteins.

How prevalent is Api g 5 sensitization among celery-allergic patients?

Research indicates that approximately 56% of Apium graveolens sensitized patients react to Api g 5 . This makes it one of the most clinically significant celery allergens, with sensitization patterns that may vary by geographical region. By comparison, Api g 1 sensitization is observed in approximately 60% of celery-allergic patients, while 26-34% of patients show sensitization to Api g 6 (LTP2) and Api g 2 (LTP1) .

Methodologically, sensitization prevalence is determined through serological testing using ELISA, ImmunoCAP, or microarray platforms with purified recombinant Api g 5. Population-based studies should include statistically significant sample sizes of clinically confirmed celery-allergic patients and account for potential cross-reactivity with homologous allergens. Regional variations should be investigated by comparing populations from different geographical areas with distinct celery consumption patterns (e.g., Central European populations predominantly consuming celery tuber versus Mediterranean populations consuming mainly celery stalks) .

What are the differences between Api g 5 and other major celery allergens?

Celery allergens differ substantially in their molecular characteristics, tissue distribution, and clinical relevance, as summarized in the following table:

Methodologically, characterizing these differences requires protein isolation using chromatographic techniques, molecular cloning, recombinant expression, immunological characterization, and tissue-specific extraction methods. Differential extraction protocols should be employed for hydrophilic proteins like Api g 1 versus lipophilic proteins like LTPs (Api g 2 and Api g 6).

Why is Api g 5 considered important for component-resolved diagnosis of celery allergy?

Api g 5 is crucial for component-resolved diagnosis because of its high sensitization prevalence (56%) and its distinct allergenic properties compared to other celery allergens . The search results indicate that in vitro diagnosis using purified Apium graveolens allergens, including Api g 5, can effectively substitute extracts that might give rise to unspecific reactivity .

Methodologically, implementing Api g 5 in component-resolved diagnosis involves:

• Expression of recombinant Api g 5 with preserved structural integrity and allergenicity

• Incorporation into multiplex assay platforms (e.g., ISAC allergen microarray, ImmunoCAP)

• Testing patient serum against Api g 5 alongside other celery components

• Correlation of component-specific sensitization patterns with clinical symptoms

• Integration of results with clinical history and other diagnostic tests

This approach helps distinguish between different sensitization patterns and clinical phenotypes. For example, patients primarily sensitized to Api g 1 often have cross-reactivity with birch pollen (indicating pollen-food allergy syndrome), while Api g 5 sensitization may indicate a different clinical phenotype .

What differential extraction methods can be used to isolate Api g 5 from natural celery sources?

Methodologically, differential extraction of Api g 5 from celery tissue requires a sequential approach to separate it from other allergens with different physicochemical properties:

• Tissue selection: Based on the available search results, researchers should determine whether Api g 5 is more abundant in celery tuber or stalks. Unlike Api g 2, which is exclusively found in stalks, or Api g 1, which is predominantly in tuber, the specific tissue distribution of Api g 5 requires empirical determination .

• Initial extraction: Homogenization of fresh celery tissue in phosphate-buffered saline (PBS) with protease inhibitors, followed by centrifugation to remove cellular debris.

• Ammonium sulfate precipitation: Sequential precipitation at different saturation levels (e.g., 0-30%, 30-60%, 60-90%) to enrich Api g 5-containing fractions.

• Ion exchange chromatography: Separation based on protein charge characteristics, typically using DEAE or Q-Sepharose at pH values optimized for Api g 5 isolation.

• Hydrophobic interaction chromatography: Particularly useful for separating Api g 5 from other celery proteins based on surface hydrophobicity differences.

• Size exclusion chromatography: Final purification step to obtain homogeneous Api g 5 preparation.

• Verification: SDS-PAGE, immunoblotting with specific anti-Api g 5 antibodies, and mass spectrometry to confirm identity and purity.

• Activity assessment: Spectroscopic analysis to verify the presence of the flavin cofactor (characteristic absorption at 350-450 nm).

This differential extraction protocol should be optimized based on the specific physicochemical properties of Api g 5 to achieve maximum yield and purity.

What expression systems are most effective for producing recombinant Api g 5 with preserved allergenicity?

The optimal expression system for recombinant Api g 5 must address several technical challenges related to its nature as a flavoprotein allergen:

• Bacterial expression (E. coli):

  • Advantages: High yield, simplicity, cost-effectiveness

  • Challenges: Flavin cofactor incorporation, proper folding, lack of post-translational modifications

  • Optimization strategies: Supplementing growth media with riboflavin, using specialized strains (e.g., Origami, SHuffle), co-expression with chaperones, fusion tags (MBP, SUMO), low-temperature induction

• Yeast expression (Pichia pastoris):

  • Advantages: Eukaryotic post-translational processing, higher folding fidelity

  • Challenges: Lower yield, longer production time

  • Optimization strategies: Codon optimization, selection of high-expression clones, optimization of induction conditions

• Insect cell expression (Baculovirus):

  • Advantages: Complex eukaryotic protein processing, suitable for conformational epitope preservation

  • Challenges: Technical complexity, higher cost

  • Optimization strategies: Optimization of multiplicity of infection, harvest timing

• Mammalian cell expression:

  • Advantages: Most authentic post-translational modifications

  • Challenges: Highest cost, lowest yield

  • Optimization strategies: Stable cell line development, optimized serum-free media

Methodologically, the choice should be guided by experimental comparison of Api g 5 produced in different systems, evaluated through structural analysis (circular dichroism, fluorescence spectroscopy) and immunological assessment (IgE binding, basophil activation) to determine which system best preserves the conformational epitopes relevant to clinical reactivity.

How can epitope mapping of Api g 5 be performed, and what are the critical factors to consider?

Epitope mapping of Api g 5 requires a multi-methodological approach to identify both linear and conformational IgE-binding regions:

• Linear epitope identification:

  • Synthesis of overlapping peptides (15-20 amino acids with 5-residue offsets) spanning the entire Api g 5 sequence

  • ELISA or microarray screening with sera from celery-allergic patients

  • Alanine scanning mutagenesis to identify critical residues within epitopes

• Conformational epitope mapping:

  • Hydrogen/deuterium exchange mass spectrometry (HDX-MS) to identify regions protected from solvent exchange when bound to IgE

  • X-ray crystallography or cryo-electron microscopy of Api g 5-antibody complexes

  • Computational epitope prediction combined with site-directed mutagenesis validation

• Cross-reactive epitope analysis:

  • Competition assays between Api g 5 and homologous allergens

  • Sequence alignment and structural comparison of potential cross-reactive epitopes

  • Inhibition ELISA using recombinant protein fragments

• Critical considerations:

  • Patient selection: Include patients with clear clinical reactivity to celery

  • Antibody source: Use both polyclonal sera and monoclonal antibodies when available

  • Structural integrity: Ensure recombinant Api g 5 maintains native conformation

  • Validation: Confirm identified epitopes functionally through directed mutations

This comprehensive approach provides a detailed epitope map that can guide the development of hypoallergenic variants for immunotherapy and improve understanding of cross-reactivity patterns with other allergens.

What methods can be used to assess the stability of Api g 5 to thermal processing and digestive enzymes?

A systematic approach to evaluating Api g 5 stability includes:

• Thermal stability assessment:

  • Heating protocols: Incubation at defined temperatures (50-100°C) for various time intervals (5-60 minutes)

  • Structural analysis: Circular dichroism spectroscopy to monitor secondary structure changes, differential scanning calorimetry for thermodynamic parameters

  • Aggregation analysis: Dynamic light scattering, size exclusion chromatography

  • Immunological assessment: IgE-binding capacity of heat-treated samples via ELISA or immunoblotting

• Simulated gastric digestion:

  • Standardized protocol: Incubation with pepsin (enzyme:protein ratio 1:20) at pH 1.2-2.0, 37°C

  • Time-course analysis: Sampling at intervals (0.5, 2, 5, 10, 20, 60 minutes)

  • Fragment analysis: SDS-PAGE, mass spectrometry identification of resistant peptides

• Simulated intestinal digestion:

  • Sequential protocol: Following gastric phase, adjust to pH 6.8-8.0, add trypsin and chymotrypsin

  • Fragment analysis: As above, identifying peptides resistant to complete digestion

  • Epitope persistence: Immunological testing of digestion products

• Functional allergenicity assessment:

  • Basophil activation test using processed/digested Api g 5

  • Skin prick testing (where ethically approved) with processed samples

  • T-cell stimulation assays to assess immunogenicity of processed forms

• Data analysis framework:

  • Kinetic modeling of degradation rates

  • Correlation between structural changes and allergenicity reduction

  • Statistical comparison with other celery allergens (Api g 1, Api g 2, etc.)

This comprehensive stability assessment provides critical information about Api g 5's ability to trigger systemic versus local allergic reactions and guides processing methods that might reduce allergenicity.

How can recombinant Api g 5 be utilized in developing hypoallergenic immunotherapy approaches for celery allergy?

Development of Api g 5-based immunotherapy involves several methodological approaches:

• Hypoallergenic variant design strategies:

  • Site-directed mutagenesis of IgE epitopes while preserving T-cell epitopes

  • Creation of fragmented peptides containing T-cell epitopes without IgE-binding capacity

  • Deletion or modification of specific structural elements required for IgE binding

  • Introduction of intramolecular disulfide bonds to stabilize non-allergenic conformations

• Production and characterization methods:

  • Expression in appropriate systems (bacterial, yeast, insect cells)

  • Purification to homogeneity using chromatographic techniques

  • Structural verification via circular dichroism, fluorescence spectroscopy

  • Verification of reduced IgE binding while maintaining T-cell recognition

• Formulation approaches:

  • Coupling to carrier proteins or adjuvants to enhance immunogenicity

  • Encapsulation in nanoparticles for targeted delivery and enhanced stability

  • Combination with immune response modifiers (CpG oligonucleotides, monophosphoryl lipid A)

• Delivery route optimization:

  • Subcutaneous: Traditional but higher risk of systemic reactions

  • Sublingual: Potentially safer with good mucosal immune response

  • Epicutaneous: Novel approach utilizing skin immune system

  • Oral: Challenging due to digestive degradation but potentially effective for food allergens

• Efficacy assessment framework:

  • Pre-clinical: Animal models to evaluate safety and immunomodulatory effects

  • Clinical: Safety assessment followed by efficacy trials using standardized food challenges

  • Biomarkers: Monitoring Api g 5-specific IgG4/IgE ratios, basophil sensitivity, cytokine profiles

• Combination approaches:

  • Multi-allergen immunotherapy including other celery components (Api g 1, Api g 2)

  • Targeting common structural features of cross-reactive allergens

These methodological approaches provide a comprehensive framework for developing Api g 5-based immunotherapy with enhanced safety and efficacy profiles.

What cross-inhibition assay designs are most effective for studying Api g 5 cross-reactivity with homologous allergens?

Cross-inhibition studies for Api g 5 require carefully designed methodological approaches:

• ELISA inhibition assay framework:

  • Plate coating: Immobilize purified natural or recombinant Api g 5

  • Serum pre-incubation: Incubate patient sera with increasing concentrations of potential cross-reactive allergens

  • Detection: Measure residual IgE binding to immobilized Api g 5

  • Analysis: Calculate inhibition percentage and IC50 values (concentration causing 50% inhibition)

• Reciprocal inhibition design:

  • Perform the reverse experiment (coat cross-reactive allergen, inhibit with Api g 5)

  • Compare inhibition potencies to determine primary sensitizer

  • Analyze asymmetric inhibition patterns that may indicate unique epitopes

• Basophil activation test inhibition:

  • Pre-incubate patient sera with potential cross-reactive allergens

  • Challenge basophils with Api g 5 and measure activation markers (CD63, CD203c)

  • Quantify functional inhibition of cellular response

• ImmunoCAP inhibition standardization:

  • Use commercial ImmunoCAP platform for standardized quantitative inhibition

  • Compare inhibition results across different patient populations

  • Correlate inhibition patterns with clinical cross-reactivity

• Mass spectrometry-based epitope mapping:

  • Identify specific peptides involved in cross-recognition

  • Perform hydrogen/deuterium exchange with antibodies pre-incubated with inhibitors

  • Pinpoint molecular regions responsible for cross-reactivity

• Critical experimental controls:

  • Self-inhibition controls (Api g 5 inhibiting itself) to establish maximum inhibition

  • Irrelevant allergen controls to verify specificity

  • Non-allergic sera controls to assess non-specific binding

• Data analysis framework:

  • Calculate and compare IC50 values across allergens

  • Develop cross-reactivity clusters based on inhibition patterns

  • Correlate with sequence homology and structural similarity

This comprehensive cross-inhibition methodology enables precise characterization of Api g 5's immunological relationship with homologous allergens from other plant sources.

How can recombinant Api g 5 be validated for use in diagnostic applications compared to natural Api g 5?

Validation of recombinant Api g 5 for diagnostic applications requires a systematic comparison with natural Api g 5 through multiple methodological approaches:

• Structural comparison methodology:

  • Circular dichroism spectroscopy: Compare secondary structure elements

  • Fluorescence spectroscopy: Evaluate tertiary structure and folding

  • Mass spectrometry: Identify post-translational modifications in natural Api g 5

  • X-ray crystallography or NMR: Compare detailed 3D structures where feasible

• Immunological equivalence assessment:

  • IgE binding comparison: ELISA with sera from celery-allergic patients

  • Quantitative comparison: ImmunoCAP inhibition assays to determine relative potency

  • Epitope coverage: Peptide microarray to verify recognition of all relevant epitopes

  • Basophil activation: Compare functional triggering of allergic effector cells

• Diagnostic performance evaluation:

  • Sensitivity and specificity determination with well-characterized patient cohorts

  • ROC curve analysis to establish optimal diagnostic cutoff values

  • Comparison of positive and negative predictive values

  • Correlation with clinical symptoms and challenge test results

• Stability and batch consistency validation:

  • Accelerated stability testing under various storage conditions

  • Lot-to-lot consistency assessment with standardized protocols

  • Robustness testing with varied experimental conditions

• Clinical validation design:

  • Prospective studies comparing diagnostic accuracy with clinical outcomes

  • Inclusion of diverse patient populations (geographic, age, symptom patterns)

  • Blinded testing versus conventional diagnostic methods

This comprehensive validation approach ensures that recombinant Api g 5 provides reliable, reproducible, and clinically relevant results in diagnostic applications, potentially substituting natural extracts that may contain variable allergen compositions .

What animal models are most appropriate for studying Api g 5 allergenicity and cross-reactivity?

Development and application of animal models for Api g 5 research requires careful consideration of methodological approaches:

• Mouse models:

  • BALB/c strain: Predisposition to Th2 responses makes it suitable for allergy models

  • Sensitization protocol: Intraperitoneal administration of purified Api g 5 with alum adjuvant followed by intranasal or oral challenges

  • Readouts: Api g 5-specific IgE/IgG1/IgG2a, cytokine profiles (IL-4, IL-5, IL-13), histopathology of relevant tissues

  • Advantages: Well-characterized immune system, availability of research tools

  • Limitations: Differences in IgE receptor distribution compared to humans

• Rat models:

  • Brown Norway rats: Higher propensity to develop IgE responses to food allergens

  • Sensitization: Oral sensitization with cholera toxin as adjuvant

  • Advantages: More pronounced IgE responses to oral allergens than mice

  • Applications: Particularly useful for gastrointestinal manifestations of celery allergy

• Humanized mouse models:

  • NOD-scid-IL2Rγnull mice engrafted with human immune cells

  • Transgenic mice expressing human FcεRI

  • Advantages: More human-relevant immune responses

  • Applications: Testing Api g 5 variants intended for human diagnostics or therapeutics

• Experimental design considerations:

  • Control groups: Include naive, adjuvant-only, and irrelevant protein controls

  • Cross-reactivity studies: Sequential sensitization to Api g 5 and homologous allergens

  • Challenge routes: Oral, respiratory, or systemic depending on research question

  • Endpoints: Both acute reactions and chronic inflammation parameters

• Validation approaches:

  • Correlation with human data when available

  • Reproducing known clinical cross-reactivity patterns

  • Predicting efficacy of candidate immunotherapeutics

These animal models provide valuable platforms for investigating Api g 5 sensitization mechanisms, cross-reactivity patterns, and testing novel diagnostic or therapeutic approaches under controlled conditions.

What mass spectrometry techniques are most effective for characterizing post-translational modifications of Api g 5?

A comprehensive mass spectrometry workflow for Api g 5 post-translational modification (PTM) analysis includes:

• Sample preparation strategies:

  • Enrichment techniques for specific PTMs (e.g., TiO2 for phosphopeptides, lectin affinity for glycopeptides)

  • Multiple proteolytic digestions (trypsin, chymotrypsin, Glu-C) to maximize sequence coverage

  • Native protein MS to determine intact mass and heterogeneity

• LC-MS/MS acquisition methods:

  • Data-dependent acquisition for discovery-based approaches

  • Parallel reaction monitoring for targeted PTM analysis

  • Electron transfer dissociation (ETD) and electron capture dissociation (ECD) for labile PTM preservation

  • Higher-energy collisional dissociation (HCD) for glycan structural information

• PTM-specific analytical approaches:

  • Glycosylation: Glycopeptide analysis with oxonium ion monitoring

  • Phosphorylation: Neutral loss scanning for phosphate groups

  • Disulfide mapping: Non-reducing versus reducing conditions

  • Flavin cofactor analysis: Specialized methods for non-covalent cofactor binding

• Quantitative analysis:

  • Label-free quantification of PTM site occupancy

  • Comparison between natural and recombinant Api g 5

  • Monitoring PTM changes during processing or storage

• Bioinformatic analysis pipeline:

  • PTM site localization algorithms (e.g., Mascot Delta Score, ptmRS)

  • Database searching with variable modifications

  • De novo sequencing for unexpected modifications

  • Structural mapping of identified PTMs

• Validation approaches:

  • Site-directed mutagenesis of identified PTM sites

  • Immunological testing of modified versus unmodified protein

  • Correlation of PTMs with allergenicity or stability properties

This comprehensive mass spectrometry approach provides detailed molecular characterization of Api g 5's PTMs, which is essential for understanding their impact on allergenicity and for producing recombinant versions that accurately mimic the natural allergen.

What methodologies can be used to investigate the role of Api g 5 in celery-mugwort cross-reactivity syndrome?

Investigation of Api g 5's potential role in celery-mugwort syndrome requires a multilayered methodological approach:

• Patient cohort characterization:

  • Selection criteria: Clear clinical reactivity to both celery and mugwort

  • Classification: Distinguishing primary celery versus primary mugwort sensitization

  • Control groups: Monosensitized patients (celery-only or mugwort-only)

  • Clinical profiling: Symptom patterns, severity, onset timing

• Molecular sensitization profiling:

  • Component-resolved diagnosis using purified allergens:

    • Celery: Api g 1, Api g 2, Api g 4, Api g 5, Api g 6

    • Mugwort: Art v 1, Art v 3 (LTP), Art v 4 (profilin), Art v 6

  • Correlation analysis between specific component sensitization patterns

• Cross-inhibition studies:

  • ELISA inhibition assays between Api g 5 and mugwort components

  • Basophil activation test inhibition studies

  • ImmunoCAP inhibition for standardized quantitative comparison

• Protein structural analysis:

  • Sequence alignment between Api g 5 and mugwort allergens

  • 3D structural modeling to identify potential shared epitopes

  • Computational epitope prediction and comparison

• T-cell cross-reactivity assessment:

  • T-cell proliferation assays with purified allergens

  • Cytokine profiling to characterize T-cell responses

  • T-cell epitope mapping and comparison

• Clinical correlation approaches:

  • Standardized challenges with celery following mugwort season

  • Longitudinal studies tracking sensitization patterns over time

  • Response to allergen-specific immunotherapy targeting either allergen source

This research framework could help determine whether Api g 5 plays a significant role in the celery-mugwort syndrome described for Central European patients , which has previously been primarily attributed to other allergens like Api g 1 (PR-10 protein) in the context of birch-celery syndrome.

How can 2D gel electrophoresis coupled with mass spectrometry be optimized for Api g 5 identification in complex celery extracts?

Optimization of 2D gel electrophoresis and mass spectrometry for Api g 5 identification requires a methodical approach:

• Sample preparation optimization:

  • Extraction buffer selection: Test multiple buffers (e.g., phosphate, Tris, HEPES) with various additives (reducing agents, detergents)

  • Protein precipitation methods: Compare TCA/acetone, methanol/chloroform, and ammonium sulfate precipitation

  • Protease inhibitor cocktails: Essential to prevent degradation during extraction

  • Contaminant removal: Specialized kits to remove polyphenols and polysaccharides abundant in plant tissues

• First dimension (isoelectric focusing) optimization:

  • pH gradient selection: Narrow-range IPG strips around Api g 5's isoelectric point

  • Sample loading methods: Cup loading versus rehydration loading

  • Focusing conditions: Step voltage protocols to improve resolution

  • Reproducibility assessment: Technical replicates to ensure consistent patterns

• Second dimension (SDS-PAGE) parameters:

  • Gel percentage optimization based on Api g 5's molecular weight

  • Gradient gels to improve resolution in specific molecular weight ranges

  • Running conditions: Temperature control and constant power settings

  • Staining methods: Comparison of sensitivity (silver, SYPRO Ruby, Coomassie)

• Spot detection and analysis:

  • Digital imaging with calibrated systems

  • Computational spot detection algorithms

  • Differential analysis between extracts (e.g., different celery tissues)

  • Matching with immunoblots using patient sera to identify allergenic spots

• Mass spectrometry workflow:

  • In-gel digestion protocols optimized for flavoproteins

  • Peptide extraction efficiency comparison

  • LC-MS/MS methods optimized for plant proteins

  • Database searching against Apiaceae protein databases and de novo sequencing

• Validation approaches:

  • Western blotting with specific anti-Api g 5 antibodies

  • Immunoaffinity purification followed by 2D gel analysis

  • Recombinant Api g 5 as positive control

This optimized methodology enables researchers to effectively identify Api g 5 and potentially discover novel isoforms or modifications in complex celery extracts, as demonstrated in previous studies where 2D gel electrophoresis identified multiple allergens from celeriac extract .